Tag: Anticoagulants
Catheter-Directed Thrombolysis Beneficial for Pulmonary Embolism
Systematic review showed risk for death and major bleeding complications was lower for catheter-directed thrombolysis than systemic thrombolysis
ASCO: Direct Oral Anticoagulant Therapy Feasible for Cancer Patients
Direct oral anticoagulants noninferior to low-molecular-weight heparin for venous thromboembolism prevention
Bleeding-Linked Hospitalization Up With Amiodarone in A-Fib
Risk up with amiodarone versus flecainide or sotalol among seniors with atrial fibrillation receiving apixaban or rivaroxaban
Risk for GI Bleed Increased With Hemodialysis Versus Peritoneal Dialysis
Furthermore, use of anticoagulants induces higher incidence of GI bleeding in hemodialysis versus peritoneal dialysis patients
Network Meta-Analysis Compares DOACs to LMWH for Cancer-Linked Thrombosis
Apixaban dominated enoxaparin and edoxaban; rivaroxaban was slightly more effective than apixaban
AHA: Once-Daily Edoxaban Seems Safe for Pediatric Cardiac Patients
Rates of clinically relevant bleeding similar between groups receiving edoxaban or standard-of-care anticoagulation
GI Bleeding Lower With Apixaban Versus Other DOACs in A-Fib
No substantial differences seen for other outcomes or for other direct oral anticoagulant comparisons
Benefit of Ticagrelor-Aspirin in Stroke Patients Tied to Renal Function
Stroke patients with normal, but not those with impaired, renal function have greater benefit with ticagrelor-aspirin than clopidogrel-aspirin
Apixaban Compared to Rivaroxaban for A-Fib and Valvular Heart Disease
Risks for ischemic stroke or systemic embolism, bleeding reduced with apixaban versus rivaroxaban for atrial fibrillation and valvular heart disease
Apixaban Noninferior to Enoxaparin for Postoperative VTE Prophylaxis
Fewer compliance events seen with apixaban versus enoxaparin for extended-duration VTE prophylaxis after abdominopelvic oncologic surgery
